anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m²/dose. The treatment is given until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.
The exploration of tumor target genes holds paramount importance for the prevention and treatment of cervical cancer. In this study, we outline the steps involved in the identification of a tumor target gene FAM83A in cervical cancer. First, the Cancer Genome Atlas dataset was employed to validate the expression and prognostic significance of FAM83A in women. A small interfering RNA (siRNA) was used for knockdown of the FAM83A gene in HeLa and C33a cells. Next, 5-ethynyl-2'-deoxyuridine (EdU) staining was conducted to determine the effects on the proliferation capabilities of the tumor cells. Wound healing and porous membrane insert assays were performed to evaluate tumor cell migration and invasion abilities. Western blotting was used to quantify apoptosis-related protein levels. JC-1 staining was employed to evaluate mitochondrial function alterations. Furthermore, cisplatin (diaminedichloroplatinum, DDP) intervention was used to assess the therapeutic potential of the target gene. Flow cytometry and colony formation assays were conducted to further validate the anticancer characteristics of the gene. As a result, FAM83A knockdown was shown to inhibit the proliferation, migration, and invasion of cervical cancer cells and sensitize these cells to cisplatin. These comprehensive methodologies collectively validate FAM83A as a tumor-associated target gene, holding promise as a potential therapeutic target in the prevention and treatment of cervical cancer.
Advanced kidney disease is a progressive life-limiting illness associated with high symptom burden, disability, and highly intensive care near the end of life. There is growing interest in integrating palliative care principles into the care of patients with advanced kidney disease to improve care and outcomes for these patients. The United States (US) Department of Veterans Affairs (VA) has been a leader in advancing palliative care initiatives across its health system and whose experience and approach may be instructive to other health systems seeking to develop kidney palliative care (KPC) services. Herein, we review current KPC programs in the VA and highlight the different models of care that programs have been adopted and how key components of goals of care conversations and advance care planning, symptom management, multidisciplinary care, patient selection, and quality improvement have been implemented across programs. VA KPC programs have adopted "parallel", "merged", and "embedded" models of KPC that reflect the different configurations of partnerships between nephrology and palliative care providers to deliver KPC. A primary service of VA KPC programs is providing goals of care conversations and advance care planning to referred patients and systematically documenting the outcomes of these discussions in standardized note templates in the electronic medical record. Symptom management is delivered by KPC providers through regular shared or sequential visits with patients' nephrology providers and is guided by patient responses to validated symptom surveys. Programs are staffed by allied health professionals, such as chaplains, pharmacists, social workers, and dieticians, to provide whole-person care and regularly huddle with nephrology staff to reach a shared understanding of each patient's care needs and plan. KPC programs implement champions who select patients in greatest need of KPC using a combination of clinical events that trigger referral for KPC and validated mortality risk prediction scores that are automatically generated in each patient's medical record. KPC programs also routinely collect clinical, patient-reported, process, and care quality measures to assess its services. The experiences of the VA highlight novel approaches that strive to close the care gaps in meeting the KPC needs of patients with advanced kidney disease.
The suture of the perineum is headed by obtaining hemostasis by digital compression 5 minutes; If hemostasis is obtained, the perineum will not be sutured. In case of failure of hemostasis, suture of the perineum will be realized.
BACKGROUND: Urine albumin (UA) is an important biomarker of chronic kidney disease. Current in vitro diagnostic medical devices (IVD-MDs) for measuring UA are not standardized, and median results among IVD-MDs differ by approximately 45%. Since fixed decision values are used to interpret UA, higher-order reference measurement procedures (RMPs) are needed for metrological traceability. Three candidate liquid chromatography-tandem mass spectrometry RMPs have been developed for UA.
METHODS: Eight single-donation human urine samples were measured by 3 candidate RMPs. Results were compared using t-test and variance component analysis.
RESULTS: The mean results for each urine sample from each RMP laboratory were not statistically different from the overall mean value by t-test. The median total CV including contributions from bias and imprecision among the 3 RMP laboratories was 6.23% using variance component analysis for each sample. The allowable bias to the RMP for an end-user IVD-MD was ≦9.0% or ≦3.0% based on the desirable or optimal total allowable error of 30% or 24%, respectively. A maximum allowable standard uncertainty for an RMP result was determined to be 4.3% or 3.3% for desirable or optimal performance, respectively. The standard uncertainties for all of the RMP laboratories meet the desirable and optimal standard uncertainty specifications.
CONCLUSION: The candidate RMPs for UA in these 3 laboratories have suitable agreement of results and uncertainties for use as higher-order RMPs in the metrological traceability of end-user IVD-MDs for measuring UA.
Palliative care is an approach that improves the quality of life of patients and their families facing problems related to life-threatening diseases. This care model focuses on meeting the physical, psychological, social and spiritual needs of patients. . Pressure ulcers are one of the most common and serious problems in palliative care. Pressure ulcers are injuries occurring on the skin or soft tissue. They develop due to pressure on certain parts of the body over a long period of time. If not treated immediately, they may cause fatal complications. Pressure ulcers affect more than 1 in 10 adult patients admitted to hospital and are highly preventable.

Most palliative care patients cannot provide self-care. Therefore, caregivers are one of the most important determinants of the patient's health status. At this point, the knowledge and skill levels of carers who provide direct care to patients are of great importance. Increasing the level of knowledge and awareness of caregivers to prevent pressure ulcers is a critical strategy to prevent the formation of these wounds and to accelerate the healing of existing wounds. In a systematic review of thirty-one articles, it was stated that pressure ulcers significantly limit many aspects of an individual's well-being, including mental and physical health and quality of life. Therefore, caregivers should have adequate knowledge about practices to prevent bedsores.

The aim of this article is to examine the effect of the training of carers caring for palliative care patients on the prevention and management of pressure ulcers. In this context, how the training affects the level of knowledge and practices of the carers will be evaluated. The findings obtained will contribute to improving the quality of patient care by providing strategic recommendations for the improvement of palliative care services.
Thyroid hormone drugs are indicated:

  1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see ). WARNINGS
  2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter.
  3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.



Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.
Sickle cell disease (SCD) is due to homozygosity for a Glu6Val mutation in HBB (sickle cell anemia; hemoglobin SS) or to compound heterozygous forms like hemoglobin SC disease and hemoglobin S-β thalassemia. Past studies suggested a low prevalence of diabetes in patients with SCD.10 Improvements in treatment and care have increased the life span of patients. This, along with the wide availability of high calorie diets and increasing adiposity in SCD raises that possibility that the prevalence of diabetes is increasing in SCD. Our study is designed to characterize the changes in metabolism that occur in sickle cell disease and to identify clinical, genetic and genomic risk factors for the development of diabetes. Our hypothesis is that non-overweight subjects with SCD have relative protection from diabetes and metabolic syndrome, but that those individuals who do become overweight have a dramatic increase in the rates of diabetes and metabolic syndrome. Lean SCD subjects will not have simply a neutral, but an overtly anti-diabetic phenotype (e.g. better glucose tolerance and lower metabolic syndrome markers). The two main study aims are as follows; Aim 1. Define the metabolic status of adult SCD subjects according to normal or increased BMI.

Aim 2. Determine genetic and genomic predictors of overweight, metabolic syndrome and diabetes in SCD subjects.
BACKGROUND: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract, but the molecular mechanisms underlying IBD are incompletely understood. In this study, we explored the role and regulating mechanism of otubain 2 (OTUB2), a deubiquitinating enzyme, in IBD.
METHODS: To study the function of OTUB2 in IBD, we generated Otub2-/- mice and treated them with dextran sulfate sodium (DSS) to induce experimental colitis. Bone marrow transplantation was performed to identify the cell populations that were affected by OTUB2 in colitis. The molecular mechanism of OTUB2 in signal transduction was studied by various biochemical methods.
RESULTS: OTUB2 was highly expressed in colon-infiltrating macrophages in both humans with IBD and mice with DSS-induced experimental colitis. Colitis was significantly aggravated in Otub2-/- mice and bone marrow chimeric mice receiving Otub2-/- bone marrow. OTUB2-deficiency impaired the production of cytokines and chemokines in macrophages in response to the NOD2 agonist muramyl dipeptide (MDP). Upon MDP stimulation, OTUB2 promoted NOD2 signaling by stabilizing RIPK2. Mechanistically, OTUB2 inhibited the proteasomal degradation of RIPK2 by removing K48-linked polyubiquitination on RIPK2, which was mediated by the active C51 residue in OTUB2. In mice, OTUB2 ablation abolished the protective effects of MDP administration in colitis.
CONCLUSION: This study identified OTUB2 as a novel regulator of intestinal inflammation.
The abducens nerve, which is vulnerable because of its complex anatomy at the skull base, is seldom affected by acute or severe sphenoid sinusitis. Notably, abducens nerve palsy following asymptomatic chronic rhinosinusitis (CRS) in a healthy young individual after a mild upper respiratory infection (URI) remains undocumented in the literature. Herein, we report a case of acute unilateral abducens neuropathy in a healthy 35-year-old woman with CRS in the ipsilateral sphenoid sinus, following a mild URI 2 weeks earlier. She presented with sudden-onset diplopia, was afebrile, and had normal serum inflammatory biomarkers. Comprehensive ophthalmological and neurological exams revealed no abnormalities except limited lateral gaze in the left eye. Imaging revealed mucosal swelling on the hyperpneumatized left sphenoid sinus, which thinned the clivus and positioned the inflamed mucosa close to the Dorello's canal, likely facilitating the spread of inflammation to the ipsilateral abducens nerve. Urgent endoscopic sinus surgery combined with systemic corticosteroids and antibiotics led to complete resolution by postoperative day 10. The present case demonstrates acute abducens nerve neuropathy from URI-induced exacerbation of sphenoid sinus CRS with specific anatomical predispositions.
PROBLEM TO BE SOLVED: To obtain the subject new compound excellent in skin whitening effect, and skin roughness preventing and improving effects, and useful as a dermal agent for external use high in safety. SOLUTION: This tranexamic acid derivative is an ester of gentisic acid with tranexamic acid expressed by the formula and salt thereof, e.g. 2-(trans-4- aminomethylcyclohexylcarbonyloxy)-5methoxybenzoic acid. The compound of the formula is obtained by reacting tranexamic acid car reactive derivative thereof with gentisic acid monomethylether in a solvent (e.g.; THF) at a room temperature to the boiling point of the solvent for 1-8hr. A dermal agent for external use such as cosmetic material and a medicine, are prepared by mixing 0.001-20wt.% ester of gentisic acid monomethylether with tranexamic acid or salt thereof as an active ingredient, preferably 0.01-7wt.% therein.
This is prospective comparative trial to assess diagnostic characteristics of non-invasive methods of liver fibrosis and steatosis assessment based on the measurement of liver stiffness. The null hypothesis is that novel device, iLivTouch FT100/FT200 and standard probe allows to obtain similar results of liver stiffness and controlled attenuation parameter compared to FibroScan 530 and probes M+ and XL+ in patients with chronic liver diseases. According to the study protocol, standard examination will be performed to eligible subjects on the same day with the use of both devices. At least 10 measurements will be performed with the use of each device to each subject after overnight fasting. The medians of liver stiffness and controlled attenuation parameter measurements, their interquartile range, success rate of measurements and related interpretations of the results (grades of liver fibrosis and steatosis) will be compared. To assess the variability of the results, demographic data (age, biological sex, ethnicity) will be collected; weight and height of the subjects will be measured on the day of examination. Medical history of the subjects will be examined to extract data, confirming the presence of chronic liver diseases and ensure eligibility.
The invention relates to the technical field of traditional Chinese medicines and provides a traditional Chinese medicine composition for treating epistaxis according to epistaxis understanding mechanism of the traditional Chinese medicine. The traditional Chinese medicine composition comprises, by weight, 8-10 parts of radix trichosanthis, 8-10 parts of white peony root and 9-11 parts of snakegourd seeds. The traditional Chinese medicine composition is decocted through water and the decoction is taken twice every day. A treatment course comprises seven days. The traditional Chinese medicine composition utilizes easily available raw materials and has good curative effects and no side effect. After a test on hundreds of epistaxis patients, a test result shows that the traditional Chinese medicine composition has an effective rate of 93% or more.
Individuals in this arm of the study will have to have a diagnosis of steroid resistant idiopathic nephrotic syndrome. They will receive transcutaneous auricular VNS (taVNS) performed for 5minutes every day for 6 months. The settings of the taVNS device will be individualized for each patient. Data will be collected on the the number of nephrotic syndrome relapses, the time between relapses, the time to remission once relapsed, and level of proteinuria before and while using taVNS therapy.
The present invention relates to a method for manufacturing an ice prunus domestica, which can heat-treat the prunus domestica fruit by a certain method, store the prunus domestica fruit in a frozen state, and then defrost and enjoy the same if necessary, and the ice prunus domestica manufactured by the same. More particularly, the method for manufacturing the ice prunus domestica comprises the steps of: removing the stem of the selected prunus domestica, and washing and dehydrating the same; removing the seeds; heat treating the selected prunus domestica at 80-100℃ for 30-60 minutes; and sealing packaging the selected prunus domestica after quenching the same. According to the present invention, the method for manufacturing ice prunus domestica which is food for frozen desserts having excellent appealability, functionality, storability, accessibility, and economy, and the ice prunus domestica manufactured by the same have increased sugar content and acidity, thereby enhancing appealability. The total polyphenol content is increased by 423%, and the total flavonoid content is increased by 133.3%. Accordingly, the active anion scavenging ability, the active cation scavenging ability and the reducing power are increased by 350%, 199% and 210%, respectively. The nitrite scavenging ability related to carcinogenesis is increased by 129.5%, which has a functionally excellent advantage. In addition, the stiffness is weakened by the heat treatment, so the prunus domestica has excellent chewability and digestibility, and can be stored for a long time if the same does not contain artificial additives. Therefore, the prunus domestica can be enjoyed all year round.
PROBLEM TO BE SOLVED: To prepare the subject preparation excellent in stability in preservation by not allowing the preparation to include an acidic protease. SOLUTION: The objective preparation does not include an acidic protease. The objective preparation preferably has <=0.01 ionic strength in terms of sodium chloride concentration and pH3-6. The objective preparation is obtained by heating a solution containing human urinary trypsin inhibitor therein to inactivate the before enzyme activities in the solution. The solution is treated by preferably raising the temperature to 60-100 deg.C under pH5-7, lowering the pH, and heating for 1-30min. Further, the objective preparation can includes 0.01-1mg/mL disaccharides such as source, or a sugar alcohol such as mannitol. the preparation can be administered to a patient in a front of injections, eye lotions, nasal drops, etc.
(CH3)2CO,CHCl3 or Et2O contains 5-15 wt. % of the reaction prod. of an N-phenyl glycine gp from (B) (D) C6H3.NH.CH(A).CO2H (where A is H or Me, B is H, Me, OMe or p-chlorophenoxy and D is H or me) and a glycidyl ether gp from p-chloropenyl glycidyl ether, the diglycidyl ether of bisphenol A or- tetrachloro bisphenol A or tetraglycidoxytetraphenylethane. The reaction prod. is obtd. by reacting a molecule of glycidyl ether and >=1 molecule of glycine to satisfy each glycidyl ether gp at 30-70 degrees C for 3-4 hrs. The soln is used as a dental primer varnish and has the advantage of increased adhesion to the resin-contg. fillings compared to the coupling agents contg. the less stable vinyl or methacrylate monomer gps.
Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate has produced multiple hepatic adenomas. TLANDO is not a 17 alpha-alkyl androgen and is not known to produce hepatic adverse effects associated with 17-alpha-alkyl androgens.  
Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue TLANDO while the cause is evaluated.
BACKGROUND: Levodopa is the gold standard of treatment in Parkinson's disease (PD). Its clinical effect changes as the disease progresses. Wearing off is a frequent first manifestation of motor fluctuations. Some patients with advanced PD report faster wearing off after physical exercise.
OBJECTIVE: The aim was to assess if pharmacokinetics of levodopa is influenced by physical exercise in patients with different disease advancement.
METHODS: 22 patients with PD (12 untreated with levodopa and 10 with motor fluctuations) and 7 healthy controls (HC) were included. Plasma samples were collected at 9 fixed timepoints following administration of levodopa/benserazide 200/50 mg for two days: rest day and standardized physical exercise day. Clinical assessment with Unified Parkinson Disease Rating Scale part III (UPDRS III) was performed in fixed timepoints. Liquid chromatography-tandem mass spectrometry was used to measure levodopa concentrations.
RESULTS: No differences between the HC, levodopa naïve and advanced PD groups were observed regarding selected pharmacokinetic parameters. In advanced PD and HC no differences in pharmacokinetic parameters of levodopa with and without effort were observed. In levodopa naïve PD group higher mean residence time after rest than after exercise (168.9±48.3 min vs. 145.5±50.8 min; p = 0.026) was observed. In advanced PD group higher UPDRS III score (14.45±5.5 versus 20.9±6.1 points, p = 0.04) was observed after exercise.
CONCLUSIONS: The deterioration of motor status of advanced PD patients after physical effort is not reflected by changes in pharmacokinetics but rather mediated by central mechanisms.
The intervention is based on an established PST protocol for medical patients, with an additional focus on HF to link depressed mood to impaired HF self-care. Seven steps are included: 1) select and define the problem; 2) establish realistic and achievable goals for problem resolutions; 3) generate multiple solution alternatives (brainstorming); 4) implement decision-making guidelines (pros and cons); 5) evaluate and choose the solutions; 6) implement the preferred solution(s); and 7) evaluate the outcome.